Emulsomes Meet S-layer Proteins: an Emerging Targeted Drug Delivery System

Overview

Journal Curr Pharm Biotechnol

Publisher Bentham Science Publishers

Specialties Biotechnology
Pharmacology

Date 2015 Feb 21

PMID 25697368

Citations 18

Authors

Mehmet H Ucisik

Uwe B Sleytr

Bernhard Schuster

Affiliations

Soon will be listed here.

Abstract

Here, the use of emulsomes as a drug delivery system is reviewed and compared with other similar lipidic nanoformulations. In particular, we look at surface modification of emulsomes using S-layer proteins, which are self-assembling proteins that cover the surface of many prokaryotic organisms. It has been shown that covering emulsomes with a crystalline S-layer lattice can protect cells from oxidative stress and membrane damage. In the future, the capability to recrystallize S-layer fusion proteins on lipidic nanoformulations may allow the presentation of binding functions or homing protein domains to achieve highly specific targeted delivery of drug-loaded emulsomes. Besides the discussion on several designs and advantages of composite emulsomes, the success of emulsomes for the delivery of drugs to fight against viral and fungal infections, dermal therapy, cancer, and autoimmunity is summarized. Further research might lead to smart, biocompatible emulsomes, which are able to protect and reduce the side effects caused by the drug, but at the same time are equipped with specific targeting molecules to find the desired site of action.

Citing Articles

SymProFold: Structural prediction of symmetrical biological assemblies.

Buhlheller C, Sagmeister T, Grininger C, Gubensak N, Sleytr U, Uson I Nat Commun. 2024; 15(1):8152.

PMID: 39294115 PMC: 11410804. DOI: 10.1038/s41467-024-52138-3.

Recent Developments in Oral Delivery of Vaccines Using Nanocarriers.

Zafar A, Arshad R, Rehman A, Ahmed N, Akhtar H Vaccines (Basel). 2023; 11(2).

PMID: 36851367 PMC: 9964829. DOI: 10.3390/vaccines11020490.

Repurposing of atorvastatin emulsomes as a topical antifungal agent.

Eita A, Makky A, Anter A, Khalil I Drug Deliv. 2022; 29(1):3414-3431.

PMID: 36428290 PMC: 9707382. DOI: 10.1080/10717544.2022.2149898.

Development and Evaluation of Novel Leflunomide SPION Bioemulsomes for the Intra-Articular Treatment of Arthritis.

Abbas H, Gad H, Sayed N, Rashed L, Khattab M, Noor A Pharmaceutics. 2022; 14(10).

PMID: 36297441 PMC: 9610779. DOI: 10.3390/pharmaceutics14102005.

Surface-tailoring of emulsomes for boosting brain delivery of vinpocetine via intranasal route: optimization and pharmacokinetic assessment.

Aldawsari H, Badr-Eldin S, Assiri N, Alhakamy N, Privitera A, Caraci F Drug Deliv. 2022; 29(1):2671-2684.

PMID: 35975309 PMC: 9387308. DOI: 10.1080/10717544.2022.2110996.

References

Pal A, Gupta S, Jaiswal A, Dube A, Vyas S . Development and evaluation of tripalmitin emulsomes for the treatment of experimental visceral leishmaniasis. J Liposome Res. 2011; 22(1):62-71. DOI: 10.3109/08982104.2011.592495. View

Ucisik M, Kupcu S, Breitwieser A, Gelbmann N, Schuster B, Sleytr U . S-layer fusion protein as a tool functionalizing emulsomes and CurcuEmulsomes for antibody binding and targeting. Colloids Surf B Biointerfaces. 2015; 128:132-139. PMC: 4406452. DOI: 10.1016/j.colsurfb.2015.01.055. View

Vyas S, Khatri K, Goyal A . Functionalized nanocarrier(s) to image and target fungi infected immune cells. Med Mycol. 2009; 47 Suppl 1:S362-8. DOI: 10.1080/13693780802464430. View

Lobenberg R, Araujo L, von Briesen H, Rodgers E, Kreuter J . Body distribution of azidothymidine bound to hexyl-cyanoacrylate nanoparticles after i.v. injection to rats. J Control Release. 1998; 50(1-3):21-30. DOI: 10.1016/s0168-3659(97)00105-3. View

Picher M, Kupcu S, Huang C, Dostalek J, Pum D, Sleytr U . Nanobiotechnology advanced antifouling surfaces for the continuous electrochemical monitoring of glucose in whole blood using a lab-on-a-chip. Lab Chip. 2013; 13(9):1780-9. DOI: 10.1039/c3lc41308j. View

Barrett J, Vardulaki K, Conlon C, Cooke J, Daza-Ramirez P, Evans E . A systematic review of the antifungal effectiveness and tolerability of amphotericin B formulations. Clin Ther. 2003; 25(5):1295-320. DOI: 10.1016/s0149-2918(03)80125-x. View

Heiati H, Phillips N, TAWASHI R . Evidence for phospholipid bilayer formation in solid lipid nanoparticles formulated with phospholipid and triglyceride. Pharm Res. 1996; 13(9):1406-10. DOI: 10.1023/a:1016090420759. View

ODriscoll C, Griffin B . Biopharmaceutical challenges associated with drugs with low aqueous solubility--the potential impact of lipid-based formulations. Adv Drug Deliv Rev. 2007; 60(6):617-24. DOI: 10.1016/j.addr.2007.10.012. View

Mehnert W, Mader K . Solid lipid nanoparticles: production, characterization and applications. Adv Drug Deliv Rev. 2001; 47(2-3):165-96. DOI: 10.1016/s0169-409x(01)00105-3. View

10.

Ucisik M, Kupcu S, Schuster B, Sleytr U . Characterization of CurcuEmulsomes: nanoformulation for enhanced solubility and delivery of curcumin. J Nanobiotechnology. 2013; 11:37. PMC: 4029586. DOI: 10.1186/1477-3155-11-37. View

11.

Dupont B . Overview of the lipid formulations of amphotericin B. J Antimicrob Chemother. 2002; 49 Suppl 1:31-6. DOI: 10.1093/jac/49.suppl_1.31. View

12.

Sandermann Jr H . Regulation of membrane enzymes by lipids. Biochim Biophys Acta. 1978; 515(3):209-37. DOI: 10.1016/0304-4157(78)90015-1. View

13.

Sleytr U . Fracture faces in intact cells and protoplasts of Bacillus stearothermophilus. A study by conventional freeze-etching and freeze-etching of corresponding fracture moieties. Protoplasma. 1970; 71(3):295-312. DOI: 10.1007/BF01279638. View

14.

Vyas S, Katare Y, Mishra V, Sihorkar V . Ligand directed macrophage targeting of amphotericin B loaded liposomes. Int J Pharm. 2001; 210(1-2):1-14. DOI: 10.1016/s0378-5173(00)00522-6. View

15.

Paliwal R, Paliwal S, Mishra N, Mehta A, Vyas S . Engineered chylomicron mimicking carrier emulsome for lymph targeted oral delivery of methotrexate. Int J Pharm. 2009; 380(1-2):181-8. DOI: 10.1016/j.ijpharm.2009.06.026. View

16.

Vollenkle C, Weigert S, Ilk N, Egelseer E, Weber V, Loth F . Construction of a functional S-layer fusion protein comprising an immunoglobulin G-binding domain for development of specific adsorbents for extracorporeal blood purification. Appl Environ Microbiol. 2004; 70(3):1514-21. PMC: 368406. DOI: 10.1128/AEM.70.3.1514-1521.2004. View

17.

Ilk N, Schumi C, Bohle B, Egelseer E, Sleytr U . Expression of an endotoxin-free S-layer/allergen fusion protein in gram-positive Bacillus subtilis 1012 for the potential application as vaccines for immunotherapy of atopic allergy. Microb Cell Fact. 2011; 10:6. PMC: 3048495. DOI: 10.1186/1475-2859-10-6. View

18.

Bjorck L, Kronvall G . Purification and some properties of streptococcal protein G, a novel IgG-binding reagent. J Immunol. 1984; 133(2):969-74. View

19.

Glew R, Saha A, Das S, Remaley A . Biochemistry of the Leishmania species. Microbiol Rev. 1988; 52(4):412-32. PMC: 373157. DOI: 10.1128/mr.52.4.412-432.1988. View

20.

Zur Muhlen A, Schwarz C, Mehnert W . Solid lipid nanoparticles (SLN) for controlled drug delivery--drug release and release mechanism. Eur J Pharm Biopharm. 1998; 45(2):149-55. DOI: 10.1016/s0939-6411(97)00150-1. View